Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)
- RESEARCH ARTICLE
Evaluation of dosing strategy for pembrolizumab for oncology indications
Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...Journal for ImmunoTherapy of Cancer 2017 5:43Published on: 16 May 2017 - RESEARCH ARTICLE
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...Journal for ImmunoTherapy of Cancer 2017 5:39Published on: 18 April 2017 - RESEARCH ARTICLE
A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood
Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...Journal for ImmunoTherapy of Cancer 2017 5:30Published on: 18 April 2017 - RESEARCH ARTICLE
Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death
We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...Journal for ImmunoTherapy of Cancer 2017 5:32Published on: 18 April 2017 - MEETING REPORT
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting
As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...Journal for ImmunoTherapy of Cancer 2017 5:38Published on: 18 April 2017 - RESEARCH ARTICLE
Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors
Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (T...Journal for ImmunoTherapy of Cancer 2017 5:37Published on: 18 April 2017 - RESEARCH ARTICLE
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...Journal for ImmunoTherapy of Cancer 2017 5:35Published on: 18 April 2017 - SHORT REPORT
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...Journal for ImmunoTherapy of Cancer 2017 5:23Published on: 21 March 2017 - RESEARCH ARTICLE
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...Journal for ImmunoTherapy of Cancer 2017 5:26Published on: 21 March 2017 - RESEARCH ARTICLE
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...Journal for ImmunoTherapy of Cancer 2017 5:22Published on: 21 March 2017 - RESEARCH ARTICLE
CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo
Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...Journal for ImmunoTherapy of Cancer 2017 5:14Published on: 21 February 2017 - CASE REPORT
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...Journal for ImmunoTherapy of Cancer 2017 5:1Published on: 17 January 2017 - RESEARCH ARTICLE
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...Journal for ImmunoTherapy of Cancer 2017 5:4Published on: 17 January 2017 - RESEARCH ARTICLE
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted a...Journal for ImmunoTherapy of Cancer 2016 4:85Published on: 20 December 2016 - RESEARCH ARTICLE
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been prev...Journal for ImmunoTherapy of Cancer 2016 4:84Published on: 20 December 2016 - RESEARCH ARTICLE
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in c...Journal for ImmunoTherapy of Cancer 2016 4:72Published on: 15 November 2016 - RESEARCH ARTICLE
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed...Journal for ImmunoTherapy of Cancer 2016 4:65Published on: 18 October 2016 - RESEARCH ARTICLE
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is...Journal for ImmunoTherapy of Cancer 2016 4:60Published on: 18 October 2016 - SHORT REPORT
High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective ...Journal for ImmunoTherapy of Cancer 2016 4:67Published on: 18 October 2016 - MEETING REPORT
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015
Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great potential for clinical application, in broad patient populations, achieving both conventional and unconvent...Journal for ImmunoTherapy of Cancer 2016 4:62Published on: 18 October 2016
.png)
No hay comentarios:
Publicar un comentario